Cameron Durrant Biography and Net Worth

CEO of Humanigen


Cameron Durrant, M.D., MBA, has served as a member and Chairman of our Board since January 2016, and as our Chief Executive Officer since March 2016. From May 2014 to January 2016, Dr. Durrant served as Founder and Director of Taran Pharma Limited, a private semi-virtual specialty pharma company developing and registering treatments in Europe for orphan conditions. Dr. Durrant served as President and Chief Executive Officer of ECR Pharmaceuticals Co., Inc., a subsidiary of Hi-Tech Pharmacal Co., Inc., from September 2012 to April 2014. From January 2010 to September 2012, Dr. Durrant served as a consultant to several biopharma companies, as the Founder, CEO, CFO and director of PediatRx, Inc. and on the boards of several privately-held healthcare companies. He previously served as CEO of PediaMed Pharmaceuticals and has been a senior executive at Johnson and Johnson, Pharmacia, GSK and Merck. Dr. Durrant served as a director of Immune Pharmaceuticals Inc. from July 2014 through August 2018 and serves on the board of directors of a privately held nano-biotech company and a medical device company. Dr. Durrant earned his medical degree from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK, his MRCGP from the Royal College of General Practitioners, London, UK, his DipCH from the Melbourne Academy, Australia and his MBA from Henley Management College, Oxford, UK. Dr. Durrant brings to the Board extensive experience as a pharma/biotech entrepreneur, operating executive and board member, as well as his day to day operating experience as our Chief Executive Officer.

How old is Cameron Durrant?

Dr. Durrant is currently 64 years old. There are 1 older executives and no younger executives at Humanigen. Learn More on Cameron Durrant's age.

How do I contact Cameron Durrant?

The corporate mailing address for Dr. Durrant and other Humanigen executives is 533 Airport Boulevard Ste. 400, Burlingame CA, 94010. Humanigen can also be reached via phone at 650-243-3100 and via email at [email protected]. Learn More on Cameron Durrant's contact information.

Has Cameron Durrant been buying or selling shares of Humanigen?

Cameron Durrant has not been actively trading shares of Humanigen during the last quarter. Most recently, on Wednesday, March 2nd, Cameron Durrant bought 40,000 shares of Humanigen stock. The stock was acquired at an average cost of $2.34 per share, with a total value of $93,600.00. Learn More on Cameron Durrant's trading history.

Who are Humanigen's active insiders?

Humanigen's insider roster includes Dale Chappell (Insider), Cameron Durrant (CEO), and Edward Jordan (Insider). Learn More on Humanigen's active insiders.

Cameron Durrant Insider Trading History at Humanigen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/2/2022Buy40,000$2.34$93,600.00View SEC Filing Icon  
6/14/2021Sell81,441$20.64$1,680,942.24View SEC Filing Icon  
See Full Table

Cameron Durrant Buying and Selling Activity at Humanigen

This chart shows Cameron Durrant's buying and selling at Humanigen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Humanigen Company Overview

Humanigen logo
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. On January 3, 2024, Humanigen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

2 Week Range

Now: N/A

Volume

59,800 shs

Average Volume

3,262,400 shs

Market Capitalization

$24,000.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A